The global actinic keratosis treatment market was valued at $1,117 million in 2018, and is projected to reach $1,558 million by 2026, registering a CAGR of 4.2% from 2019 to 2026.
Actinic keratosis (AK) is the most common precancer that forms on skin damaged by long-term exposure to ultraviolet radiation from the sun and/or indoor tanning. It is characterized by rough, scaly patch on skin most commonly found on your face, lips, ears, back of your hands, forearms, scalp, or neck. Surgical procedures, topical treatments, photodynamic therapy, and combination therapy are used for the treatment of actinic keratosis. Drug such as 5-fluorouracil, diclofenac, imiquimod, and ingenol mebutate have been approved for the treatment of actinic keratosis.
Increase in prevalence of actinic keratosis, preferable use of topical therapeutics, potential drugs in pipeline, rise in demand for actinic keratosis treatment products, growth in geriatric population, and wide availability of therapeutics are the major factors that drive the growth of the actinic keratosis treatment market. For instance, according to the Skin Cancer Foundation, actinic keratosis is the most common precancer and it affects more than 58 million Americans. In addition, according to article published in News Medical the overall rate of actinic keratosis in the U.S. is estimated to be approximately 10.2% in females and 26.5% in males. In addition, increase in adoption of topical treatment for actinic keratosis, easy accessibility to therapeutics, and rise in healthcare expenditure are other factors that contribute toward the growth of the market. Potential pipeline drugs are AM-001, GDC 695, Tirbanibulin, Tuvatexib and others will further drive the market growth. However, availability of alternate treatment is expected to hinder the market growth.
Actinic Keratosis Treatment Market Segmentation
The actinic keratosis treatment market is segmented on the basis of drug type, type, distribution channel, and region. By drug type, the market is categorized into fluorouracil, imiquimod, diclofenac, and others. On the basis of type, the market is bifurcated into prescription and OTC. According to distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Based on region, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Segment Review
Based on drug type, the market is segmented into fluorouracil, imiquimod, diclofenac, and others. Presently fluorouracil segment dominates the global market, and is anticipated to continue this trend over the forecast period. The key factors that drive the market growth include use of fluorouracil as a first line treatment, increase in demand & cost effectivity, and wide availability of fluorouracil act as the key factors that significantly contribute toward the growth of the market.
By Drug Type
Imiquimod is projected as one of the most lucrative segment.
According to distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The online providers segment is anticipated to depict significant growth during the forecast period due to rise in preference for online purchasing of drugs over the traditional methods, increase in awareness of online pharmacy, and rise in number of internet users.
By Distribution Channel
Drug Stores And Retail Pharmacies holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.
Snapshot of Asia-Pacific Actinic Keratosis Treatment Market
Asia-Pacific presents lucrative opportunities for the key players operating in the actinic keratosis treatment market. Some key factors such as increase in awareness toward actinic keratosis treatment, growth in prevalence of actinic keratosis, improvement in healthcare infrastructure, the developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare are contributing toward the market growth in this region.
In addition, surge in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market is expected to drive the growth of the actinic keratosis treatment market in Asia-Pacific.
By Geography
Asia-Pacific region would exhibit the highest CAGR of 6.3% during 2019-2026.
The key players profiled in this report include 3M Company, Almirall, S.A., Bausch Health Companies Inc., Biofrontera, Inc., Hill Dermaceuticals, Inc., LEO Pharma A/S, Mylan N.V., Novartis AG, Stanford Chemicals, and Sun Pharmaceutical Industries Ltd. (DUSA Pharmaceuticals, Inc.).
Key Benefits for Stakeholders:
- The study provides an in-depth analysis of the actinic keratosis treatment market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers Actinic keratosis treatment market analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
- A comprehensive analysis of all the major geographical regions is provided to determine the prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global actinic keratosis treatment market growth.
Actinic Keratosis Treatment Market Report Highlights
| Aspects | Details |
 By Drug Type |
|
 By Type |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Novartis AG, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd. (DUSA Pharmaceuticals, Inc.), Bausch Health Companies Inc., Hill Dermaceuticals, Inc., Stanford Chemicals, Biofrontera, Inc., Mylan N.V, 3M Company, Almirall, S.A. |
Analyst Review
Actinic keratosis is most commonly found on face, lips, ears, back of your hands, forearms, scalp, and neck. Actinic keratosis can be treated using different therapies such as surgical procedures, topical treatments, photodynamic therapy, and combination therapy. However, topical therapeutics such as fluorouracil, imiquimod, and diclofenac are preferably used in the treatment.
Surge in R&D for the innovation of new products and preferable use of actinic keratosis topical treatment significantly boost the growth of the actinic keratosis treatment market. Moreover, rise in geriatric population, growth in incidence of actinic keratosis, and rise in adoption of topical treatments further drive the market growth. However, availability of alternative treatments are expected to restrain the growth of the market.
North America is expected to remain dominant during the forecast period due to higher prevalence of actinic keratosis with increase in healthcare awareness and presence of pipeline drugs under various stages of clinical trials. In addition, Asia-Pacific are expected to offer lucrative opportunities to the key players during the forecast period due to rise in prevalence of actinic keratosis in countries such as Australia and New Zealand.
The market value of global actinic keratosis market was $1,116.7 million in 2018.
The forecast period is from 2019 to 2026.
The market value of global actinic keratosis market in 2019 is $1,165.2 million.
The adoption of actinic keratosis is expected to increase in prevalence of actinic keratosis, use of topical therapeutics as a first line treatment option, rise in demand for actinic keratosis therapeutics, strong presence of pipeline drugs, and rise in geriatric population are the key factors that fuel the growth of the actinic keratosis treatment market
The base year calculated in the report is 2018.
Yes, Novartis is profiled in the report.
Emerging countries of Asia-Pacific region are growing at a growth% of 6.3%. Japan, China, Australia, are expected grow at a CAGR of 6.9%, 4.6%, 8.1% respectively.
The North America market held a major share in the actinic keratosis market in 2018 and is expected to continue the trend in the forecasting period. This is attributed to rise in demand for actinic keratosis treatment drugs, presence of advanced healthcare facilities with trained medical professionals, and surge in number of R & D activities to develop actinic keratosis therapeutics, thereby contributing toward the growth of the North America market.
Loading Table Of Content...
